Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K.
Hu J, et al. Among authors: menu e.
Blood. 2010 Sep 2;116(9):1524-7. doi: 10.1182/blood-2010-02-269126. Epub 2010 Jun 7.
Blood. 2010.
PMID: 20530289
Free article.